Abstract:As the most lethal gynecologic oncological indication, carcinoma of the ovary has been ranked as the 5th cause of cancer-related mortality in women, with a high percentage of the patients being diagnosed at late stages of the disease and a five-year survival of ~ 30%. Ovarian cancer patients conventionally undergo surgery for tumor removal followed by platinum- or taxane-based chemotherapy; however, a high percentage of patients experience tumor relapse. Cancer immunotherapy has been regarded as a silver lining in the treatment of patients with various immunological or oncological indications; however, mirvetuximab soravtansine (a folate receptor α-specific mAb) and bevacizumab (a VEGF-A-specific mAb) are the only immunotherapeutics approved for the treatment of ovarian cancer patients. Chimeric antigen receptor T-cell (CAR-T) therapy has achieved tremendous clinical success in the treatment of patients with certain B-cell lymphomas and leukemias, as well as multiple myeloma. In the context of solid tumors, CAR-T therapies face serious obstacles that limit their therapeutic benefit. Such hindrances include the immunosuppressive nature of solid tumors, impaired tumor infiltration, lack of qualified tumor-associated antigens, and compromised stimulation and persistence of CAR-Ts following administration. Over the past years, researchers have made arduous attempts to apply CAR-T therapy to ovarian cancer. In this review, we outline the principles of CAR-T therapy and then highlight its limitations in the context of solid tumors. Ultimately, we focus on preclinical and clinical findings achieved in CAR-T-mediated targeting of different ovarian cancer-associated target antigens.

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

The emerging field of oncolytic virus-based cancer immunotherapy

Oncolytic virus enhanced CAR T cell therapy in killing solid tumors

Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer

Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option

Current Landscape and Perspective of Oncolytic Viruses and Their Combination Therapies.

CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

Application of oncolytic virus in tumor therapy

Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Oncolytic virotherapy: basic principles, recent advances and future directions